| 1 | CDKN2A, TIMP3
|
| P14ARF inhibits regional inflammation and vascularization in intervertebral disc degeneration by upregulating TIMP3.
|
| He M, Pang J, Sun H, Zheng G, Lin Y, Ge W.
|
| Am J Physiol Cell Physiol 318(4):C751-C761. doi: 10.1152/ajpcell.00271.2019. Epub 2020 Feb 5.
2020
|
| 2 | CDKN2A, PIAS1
|
| Tumor Suppressor p14ARF Enhances IFN-γ-Activated Immune Response by Inhibiting PIAS1 via SUMOylation.
|
| Alagu J, Itahana Y, Sim F, Chao SH, Bi X, Itahana K.
|
| J Immunol 201(2):451-464. doi: 10.4049/jimmunol.1800327. Epub 2018 May 30.
2018
|
| 3 | CDKN2A, CDKN2B
|
| Oxidative stress levels are correlated with P15 and P16 gene promoter methylation in myelodysplastic syndrome patients.
|
| Gonçalves AC, Cortesão E, Oliveiros B, Alves V, Espadana AI, Rito L, Magalhães E, Pereira S, Pereira A, Costa JM, Mota-Vieira L, Sarmento-Ribeiro AB.
|
| Clin Exp Med 16(3):333-43. doi: 10.1007/s10238-015-0357-2. Epub 2015 May 17.
2016
|
| 4 | ARF, CDKN2A, HUWE1
|
| Syk-mediated tyrosine phosphorylation of mule promotes TNF-induced JNK activation and cell death.
|
| Lee CK, Yang Y, Chen C, Liu J.
|
| Oncogene 35(15):1988-95. doi: 10.1038/onc.2015.275. Epub 2015 Jul 27.
2016
|
| 5 | CDKN2A, VHL
|
| Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein.
|
| Minervini G, Mazzotta GM, Masiero A, Sartori E, Corrà S, Potenza E, Costa R, Tosatto SC.
|
| Sci Rep 5:12605. doi: 10.1038/srep12605.
2015
|
| 6 | CDKN2A, KL
|
| Ablation of the p16(INK4a) tumour suppressor reverses ageing phenotypes of klotho mice.
|
| Sato S, Kawamata Y, Takahashi A, Imai Y, Hanyu A, Okuma A, Takasugi M, Yamakoshi K, Sorimachi H, Kanda H, Ishikawa Y, Sone S, Nishioka Y, Ohtani N, Hara E.
|
| Nat Commun 6:7035. doi: 10.1038/ncomms8035.
2015
|
| 7 | CDKN2A, CDKN2B, STAT5B
|
| Control of CD8 T cell proliferation and terminal differentiation by active STAT5 and CDKN2A/CDKN2B.
|
| Grange M, Giordano M, Mas A, Roncagalli R, Firaguay G, Nunes JA, Ghysdael J, Schmitt-Verhulst AM, Auphan-Anezin N.
|
| Immunology 145(4):543-57. doi: 10.1111/imm.12471. Epub 2015 Jun 15.
2015
|
| 8 | CDKN2A, FBXW11
|
| S6 Kinase- and β-TrCP2-Dependent Degradation of p19Arf Is Required for Cell Proliferation.
|
| Nakagawa T, Araki T, Nakagawa M, Hirao A, Unno M, Nakayama K.
|
| Mol Cell Biol 35(20):3517-27. doi: 10.1128/MCB.00343-15. Epub 2015 Aug 3.
2015
|
| 9 | CDKN2A, CDKN2B
|
| Aberrant promoter methylation of p15 (INK⁴b) and p16 (INK⁴a) genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis.
|
| Wang X, Zhu YB, Cui HP, Yu TT.
|
| Tumour Biol 35(9):9035-43. doi: 10.1007/s13277-014-2054-2. Epub 2014 Jun 8.
2014
|
| 10 | CDKN2A, NPM1, TMUB1
|
| Different functions of HOPS isoforms in the cell: HOPS shuttling isoform is determined by RIP cleavage system
|
| Castelli M, Piobbico D, Bartoli D, Pieroni S, Brunacci C, Bellet MM, Chiacchiaretta M, Della Fazia MA, Servillo G.
|
| Cell Cycle. 13(2):293-302. doi: 10.4161/cc.27054. Epub 2013 Feb 1. 2014
|
| 11 | CDKN2A, PVT1
|
| Deletion or methylation of CDKN2A/2B and PVT1 rearrangement occur frequently in highly aggressive B-cell lymphomas harboring 8q24 abnormality.
|
| Tsutsumi Y, Chinen Y, Sakamoto N, Nagoshi H, Nishida K, Kobayashi S, Yokokawa Y, Taki T, Sasaki N, Yamamoto-Sugitani M, Kobayashi T, Matsumoto Y, Horiike S, Kuroda J, Taniwaki M.
|
| Leuk Lymphoma 54(12):2760-4. doi: 10.3109/10428194.2013.790543. Epub 2013 May 9. No abstract available.
2013
|
| 12 | CDKN2A, EEF1A2
|
| Tumor suppressor p16(INK4a) inhibits cancer cell growth by downregulating eEF1A2 through a direct interaction.
|
| Lee MH, Choi BY, Cho YY, Lee SY, Huang Z, Kundu JK, Kim MO, Kim DJ, Bode AM, Surh YJ, Dong Z.
|
| J Cell Sci 126(Pt 8):1744-52. doi: 10.1242/jcs.113613. Epub 2013 Feb 26. Erratum in: J Cell Sci. 2013 Aug 15;126(Pt 16):3796.
2013
|
| 13 | CDKAL1, CDKN2A, CDKN2B
|
| The relationship between five widely-evaluated variants in CDKN2A/B and CDKAL1 genes and the risk of type 2 diabetes: a meta-analysis.
|
| Peng F, Hu D, Gu C, Li X, Li Y, Jia N, Chu S, Lin J, Niu W.
|
| Gene 531(2):435-43. doi: 10.1016/j.gene.2013.08.075. Epub 2013 Sep 4.
2013
|
| 14 | CDKN2A, CDKN2B, DLC1
|
| Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer.
|
| Qian X, Durkin ME, Wang D, Tripathi BK, Olson L, Yang XY, Vass WC, Popescu NC, Lowy DR.
|
| Cancer Res 72(22):5900-11. doi: 10.1158/0008-5472.CAN-12-2368. Epub 2012 Sep 25.
2012
|
| 15 | CDKN2A, MKRN1
|
| Acceleration of gastric tumorigenesis through MKRN1-mediated posttranslational regulation of p14ARF.
|
| Ko A, Shin JY, Seo J, Lee KD, Lee EW, Lee MS, Lee HW, Choi IJ, Jeong JS, Chun KH, Song J.
|
| J Natl Cancer Inst 104(21):1660-72. doi: 10.1093/jnci/djs424. Epub 2012 Oct 25.
2012
|
| 16 | CDKN2A, TRADD, TRIP12
|
| TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylation.
|
| Chio II, Sasaki M, Ghazarian D, Moreno J, Done S, Ueda T, Inoue S, Chang YL, Chen NJ, Mak TW.
|
| Nat Cell Biol 14(6):625-33. doi: 10.1038/ncb2496.
2012
|
| 17 | CDKN2A, NMI
|
| NMI mediates transcription-independent ARF regulation in response to cellular stresses.
|
| Li Z, Hou J, Sun L, Wen T, Wang L, Zhao X, Xie Q, Zhang SQ.
|
| Mol Biol Cell 23(23):4635-46. doi: 10.1091/mbc.E12-04-0304. Epub 2012 Oct 3.
2012
|
| 18 | CDKN2A, RNF2
|
| RING1B ubiquitination and stability are regulated by ARF.
|
| de Bie P, Ciechanover A.
|
| Biochem Biophys Res Commun 426(1):49-53. doi: 10.1016/j.bbrc.2012.08.030.
2012
|
| 19 | CDKN2A, E2F1, HNRNPD
|
| p16( INK4a) positively regulates cyclin D1 and E2F1 through negative control of AUF1.
|
| Al-Khalaf HH, Colak D, Al-Saif M, Al-Bakheet A, Hendrayani SF, Al-Yousef N, Kaya N, Khabar KS, Aboussekhra A.
|
| PLoS One 6(7):e21111. Epub 2011 Jul 20.
2011
|
| 20 | CDKN2A, EZH2, PDGFA, PDGFRA, PDGFRB
|
| PDGF signalling controls age-dependent proliferation in pancreatic β-cells.
|
| Chen H, Gu X, Liu Y, Wang J, Wirt SE, Bottino R, Schorle H, Sage J, Kim SK.
|
| Nature 478(7369):349-55. doi: 10.1038/nature10502.
2011
|
| 21 | CDKN2A, CDKN2B, CDKN2B-AS1
|
| Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression.
|
| Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B.
|
| PLoS Genet 6(4):e1000899. 2010
|
| 22 | CDKN2A
|
| Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk.
|
| Sherborne AL, Hosking FJ, Prasad RB, Kumar R, Koehler R, Vijayakrishnan J, Papaemmanuil E, Bartram CR, Stanulla M, Schrappe M, Gast A, Dobbins SE, Ma Y, Sheridan E, Taylor M, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Moorman AV, Harrison CJ, Tomlinson IP, Richards S, Zimmermann M, Szalai C, Semsei AF, Erdelyi DJ, Krajinovic M, Sinnett D, Healy J, Gonzalez Neira A, Kawamata N, Ogawa S, Koeffler HP, Hemminki K, Greaves M, Houlston RS.
|
| Nat Genet 42(6):492-4. Epub 2010 May 9.PMID: 20453839 2010
|
| 23 | BMI1, CDKN2A, RNF2
|
| Identification and characterization of Bmi-1-responding element within the human p16 promoter.
|
| Meng S, Luo M, Sun H, Yu X, Shen M, Zhang Q, Zhou R, Ju X, Tao W, Liu D, Deng H, Lu Z.
|
| J Biol Chem 285(43):33219-29. Epub 2010 Jun 15. 2010
|
| 24 | CDKN2A, ZNF420
|
| ARF-dependent regulation of ATM and p53 associated KZNF (Apak) protein activity in response to oncogenic stress.
|
| Wang S, Tian C, Xing G, Gao M, Jiao W, Xiao T, Yin Y, He F, Zhang L.
|
| FEBS Lett 584(18):3909-15. Epub 2010 Aug 14.
2010
|
| 25 | CDKN2A, SMARCA4
|
| The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a.
|
| Becker TM, Haferkamp S, Dijkstra MK, Scurr LL, Frausto M, Diefenbach E, Scolyer RA, Reisman DN, Mann GJ, Kefford RF, Rizos H.
|
| Mol Cancer 8:4.
2009
|
| 26 | CDKN2A, XPC
|
| ARF stimulates XPC to trigger nucleotide excision repair by regulating the repressor complex of E2F4.
|
| Dominguez-Brauer C, Chen YJ, Brauer PM, Pimkina J, Raychaudhuri P.
|
| EMBO Rep 10(9):1036-42. Epub 2009 Jul 31.
2009
|
| 27 | ASIP, CDK4, CDKN2A, CMM1, CMM2, CMM20, CMM3, CMM4, MC1R, TYR, TYRP1
|
| Genetic risk factors for melanoma.
|
| Meyle KD, Guldberg P.
|
| Hum Genet 126(4):499-510. Epub 2009 Jul 8. Review.
2009
|
| 28 | CDKN2A, IGFBP2
|
| IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas.
|
| Moore LM, Holmes KM, Smith SM, Wu Y, Tchougounova E, Uhrbom L, Sawaya R, Bruner JM, Fuller GN, Zhang W.
|
| Proc Natl Acad Sci U S A 106(39):16675-9. Epub 2009 Sep 16.PMID: 19805356 2009
|
| 29 | CDKN2A, CDKN2B
|
| Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study.
|
| Kim M, Yim SH, Cho NS, Kang SH, Ko DH, Oh B, Kim TY, Min HJ, She CJ, Kang HJ, Shin HY, Ahn HS, Yoon SS, Kim BK, Shin HR, Han KS, Cho HI, Lee DS.
|
| Cancer Genet Cytogenet 195(1):59-65.PMID: 19837270 2009
|
| 30 | CDKN2A, CDKN2B
|
| Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood.
|
| Novara F, Beri S, Bernardo ME, Bellazzi R, Malovini A, Ciccone R, Cometa AM, Locatelli F, Giorda R, Zuffardi O.
|
| Hum Genet 126(4):511-20. Epub 2009 May 30.PMID: 19484265 2009
|
| 31 | CBX7, CDKN2A
|
| Several distinct polycomb complexes regulate and co-localize on the INK4a tumor suppressor locus.
|
| Maertens GN, El Messaoudi-Aubert S, Racek T, Stock JK, Nicholls J, Rodriguez-Niedenführ M, Gil J, Peters G.
|
| PLoS One 4(7):e6380.PMID: 19636380 2009
|
| 32 | REM2, CDKN2A
|
| An endothelial cell genetic screen identifies the GTPase Rem2 as a suppressor of p19ARF expression that promotes endothelial cell proliferation and angiogenesis.
|
| Bierings R, Beato M, Edel MJ.
|
| J Biol Chem 283(7):4408-16. Epub 2007 Dec 3. 2008
|
| 33 | APC, BRCA1, BRCA2, CDH1, CDKN2A, MLH1, MSH2, MSH6, PMS2, PRSS1, PTEN, RB1, SPINK1, STK11, TP53
|
| Inherited susceptibility to common cancers.
|
| Foulkes WD.
|
| N Engl J Med 359(20):2143-53. No abstract available.
2008
|
| 34 | ANAPC1, CDKN2A
|
| Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer.
|
| Lima EM, Leal MF, Burbano RR, Khayat AS, Assumpção PP, Bello MJ, Rey JA, Smith MA, Casartelli C.
|
| Braz J Med Biol Res 41(6):539-43.PMID: 18622497 2008
|
| 35 | CMM2, CDKN2A, DEL9P
|
| Multiple primary tumors associated with chromosome 9p deletion.
|
| Lindor NM, Jalal SM, Kumar S, Lteif AN.
|
| Am J Med Genet A 143(1):95-7. No abstract available. 2007
|
| 36 | CDKN2A ,CMM2
|
| Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.
|
| Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Timothy Bishop D, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Cannon Albright LA, Chaudru V, Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Teresa Landi M, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E.
|
| J Med Genet 44(2):99-106. Epub 2006 Aug 11. 2007
|
| 37 | CDKN2A,CDKN2B
|
| A common allele on chromosome 9 associated with coronary heart disease.
|
| McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC.
|
| Science 316(5830):1488-91. Epub 2007 May 3. 2007
|
| 38 | CDKN2A,CDKN2B, ANRIL
|
| A common variant on chromosome 9p21 affects the risk of myocardial infarction.
|
| Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, Masson G, Gudbjartsson DF, Magnusson KP, Andersen K, Levey AI, Backman VM, Matthiasdottir S, Jonsdottir T, Palsson S, Einarsdottir H, Gunnarsdottir S, Gylfason A, Vaccarino V, Hooper WC, Reilly MP, Granger CB, Austin H, Rader DJ, Shah SH, Quyyumi AA, Gulcher JR, Thorgeirsson G, Thorsteinsdottir U, Kong A, Stefansson K.
|
| Science 316(5830):1491-3. Epub 2007 May 3. 2007
|
| 39 | CDKN2A, ISOC2
|
| Identification and characterization of a novel protein ISOC2 that interacts with p16INK4a.
|
| Huang X, Shi Z, Wang W, Bai J, Chen Z, Xu J, Zhang D, Fu S.
|
| Biochem Biophys Res Commun 361(2):287-93. Epub 2007 Jul 16. 2007
|
| 40 | CDKN2A, PSMC3
|
| TBP-1 protects the human oncosuppressor p14ARF from proteasomal degradation.
|
| Pollice A, Sepe M, Villella VR, Tolino F, Vivo M, Calabrò V, La Mantia G.
|
| Oncogene 26(35):5154-62. Epub 2007 Mar 5.
2007
|
| 41 | CDKN2A, CDKN2B, MNST
|
| Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.
|
| Laud K, Marian C, Avril MF, Barrois M, Chompret A, Goldstein AM, Tucker MA, Clark PA, Peters G, Chaudru V, Demenais F, Spatz A, Smith MW, Lenoir GM, Bressac-de Paillerets B; French Hereditary Melanoma Study Group.
|
| J Med Genet 43(1):39-47. Epub 2005 Jun 3. 2006
|
| 42 | CDKN2A, MNST
|
| A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
|
| Knappskog S, Geisler J, Arnesen T, Lillehaug JR, Lonning PE.
|
| Genes Chromosomes Cancer 45(12):1155-63. 2006
|
| 43 | CDKN2A, CDKN2B
|
| The regulation of INK4/ARF in cancer and aging.
|
| Kim WY, Sharpless NE.
|
| Cell 127(2):265-75. Review. 2006
|
| 44 | CDKN1A, CDKN1B, CDKN2A, RB1
|
| Age differences in cyclin-dependent kinase inhibitor expression and rb hyperphosphorylation in human corneal endothelial cells.
|
| Enomoto K, Mimura T, Harris DL, Joyce NC.
|
| Invest Ophthalmol Vis Sci 47(10):4330-40. 2006
|
| 45 | CDKN2A, ING1
|
| A functional link between the tumour suppressors ARF and p33ING1.
|
| Gonz‡lez L, Freije JM, Cal S, L—pez-Ot’n C, Serrano M, Palmero I.
|
| Oncogene 25(37):5173-9. Epub 2006 Apr 10. 2006
|
| 46 | CDKN2A, UBTF
|
| Human tumor suppressor p14ARF negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation.
|
| Ayrault O, Andrique L, Fauvin D, Eymin B, Gazzeri S, Séité P.
|
| Oncogene 25(58):7577-86. Epub 2006 Aug 21.
2006
|
| 47 | CDKN2A
|
| A common variant of CDKN2A (p16) predisposes to breast cancer.
|
| Debniak T, Gorski B, Huzarski T, Byrski T, Cybulski C, Mackiewicz A, Gozdecka-Grodecka S, Gronwald J, Kowalska E, Haus O, Grzybowska E, Stawicka M, Swiec M, Urbanski K, Niepsuj S, Wasko B, Gozdz S, Wandzel P, Szczylik C, Surdyka D, Rozmiarek A, Zambrano O, Posmyk M, Narod SA, Lubinski J.
|
| J Med Genet 42(10):763-5. Epub 2005 May 6. 2005
|
| 48 | CDKN2A, PSMC3
|
| Functional and physical interaction of the human ARF tumor suppressor with Tat-binding protein-1.
|
| Pollice A, Nasti V, Ronca R, Vivo M, Lo Iacono M, Calogero R, Calabrò V, La Mantia G.
|
| J Biol Chem 279(8):6345-53. Epub 2003 Dec 9.
2004
|
| 49 | CDKN2A
|
| Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells.
|
| Florl AR, Schulz WA.
|
| Genes Chromosomes Cancer 37(2):141-8. 2003
|
| 50 | CDKN2A
|
| CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
|
| Kannengiesser C, Avril MF, Spatz A, Laud K, Lenoir GM, Bressac-de-Paillerets B.
|
| Genes Chromosomes Cancer 38(3):265-8. 2003
|
| 51 | CDKN2A, CDKN2B
|
| Loss of 9p21 is embedded in a complex but consistent pattern of genomic imbalances in oral squamous cell carcinomas.
|
| Gebhart E, Liehr T, Wolff E, Wiltfang J, Koscielny S, Ries J.
|
| Cytogenet Genome Res 101(2):106-12. 2003
|
| 52 | CDKN2A,DAPK1,GSRP1
|
| The power and the promise of DNA methylation markers.
|
| Laird PW.
|
| Nat Rev Cancer 3(4):253-66. Review. 2003
|
| 53 | CDKN2A
|
| Germline mutation of ARF in a melanoma kindred.
|
| Hewitt C, Lee Wu C, Evans G, Howell A, Elles RG, Jordan R, Sloan P, Read AP, Thakker N.
|
| Hum Mol Genet 11(11):1273-9. 2002
|
| 54 | CDKN2A, DLC1, EXT1, MLH1, PTEN, RB1, TP53, TP73
|
| Molecular pathogenesis of human hepatocellular carcinoma.
|
| Thorgeirsson SS, Grisham JW.
|
| Nat Genet 31(4):339-46. 2002
|
| 55 | BCL2, CDKN2A, MYC, RB1, TSG3B
|
| Cytogenetics and molecular genetics of lung cancer.
|
| Mitsuuchi Y, Testa JR.
|
| Am J Med Genet 115(3):183-8. 2002
|
| 56 | CDKN2A, CDKN2B
|
| Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors.
|
| Arcellana-Panlilio MY, Egeler RM, Ujack E, Magliocco A, Stuart GC, Robbins SM, Coppes MJ.
|
| Genes Chromosomes Cancer 35(2):176-81. 2002
|
| 57 | CDKN2A, MDM2
|
| P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2.
|
| Xirodimas DP, Chisholm J, Desterro JM, Lane DP, Hay RT.
|
| FEBS Lett 528(1-3):207-11. 2002
|
| 58 | SFN, CDKN2A
|
| Coincident inactivation of 14-3-3sigma and p16INK4a is an early event in vulval squamous neoplasia.
|
| Gasco M, Sullivan A, Repellin C, Brooks L, Farrell PJ, Tidy JA, Dunne B, Gusterson B, Evans DJ, Crook T.
|
| Oncogene 21(12):1876-81. 2002
|
| 59 | CDKN2A
|
| Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
|
| Smeds J, Berggren P, Ma X, Xu Z, Hemminki K, Kumar R.
|
| Carcinogenesis 23(4):645-55. 2002
|
| 60 | CDKN2A, MDM2
|
| Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland.
|
| Foster CJ, Lozano G.
|
| Oncogene 21(22):3525-31. 2002
|
| 61 | CDKN2A, CDKN2AIP
|
| CARF is a novel protein that cooperates with mouse p19ARF (human p14ARF) in activating p53.
|
| Hasan MK, Yaguchi T, Sugihara T, Kumar PK, Taira K, Reddel RR, Kaul SC, Wadhwa R.
|
| J Biol Chem 277(40):37765-70. Epub 2002 Aug 01. 2002
|
| 62 | XPC, CDKN2A
|
| Germline and somatic mutations of the INK4a-ARF gene in a xeroderma pigmentosum group C patient.
|
| Soufir N, Ribojad M, Magnaldo T, Thibaudeau O, Delestaing G, Daya-Grosjean L, Rivet J, Sarasin A, Basset-Seguin N.
|
| J Invest Dermatol 119(6):1355-60. 2002
|
| 63 | FAMMMPC, CDKN2A
|
| Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
|
| Lynch HT, Brand RE, Hogg D, Deters CA, Fusaro RM, Lynch JF, Liu L, Knezetic J, Lassam NJ, Goggins M, Kern S.
|
| Cancer 94(1):84-96. 2002
|
| 64 | CDKN2A, FAMMMPC
|
| CDKN2A germline mutations in familial pancreatic cancer.
|
| Bartsch DK, Sina-Frey M, Lang S, Wild A, Gerdes B, Barth P, Kress R, Grutzmann R, Colombo-Benkmann M, Ziegler A, Hahn SA, Rothmund M, Rieder H.
|
| Ann Surg 236(6):730-7. 2002
|
| 65 | CDKN2A, CDKN2B, MNST
|
| A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.
|
| Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Newton Bishop J , Bishop DT.
|
| Hum Mol Genet 10(1):55-62. 2001
|
| 66 | CDKN2A
|
| A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees.
|
| Harland M, Mistry S, Bishop DT, Bishop JA.
|
| Hum Mol Genet 10(23):2679-86. 2001
|
| 67 | CDKN2A
|
| Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma.
|
| Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS.
|
| Cancer Res 61(2):679-86. 2001
|
| 68 | CDKN2A, ID1
|
| The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas.
|
| Polsky D, Young AZ, Busam KJ, Alani RM.
|
| Cancer Res 61(16):6008-11. 2001
|
| 69 | CDKN2A, ETS1, ETS2, ID1
|
| Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence.
|
| Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, Sharrocks AD, Peters G, Hara E.
|
| Nature 409(6823):1067-70. 2001
|
| 70 | CDKN2A
|
| Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers.
|
| Sanchez-Cespedes M, Decker PA, Doffek KM, Esteller M, Westra WH, Alawi EA, Herman JG, Demeure MJ, Sidransky D, Ahrendt SA.
|
| Cancer Res 61(5):2092-6. 2001
|
| 71 | CDKN2A, CDKN2B
|
| Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas.
|
| Bisogna M, Calvano JE, Ho GH, Orlow I, Cordon-Cardo C, Borgen PI, Van Zee KJ.
|
| Cancer Genet Cytogenet 125(2):131-8. 2001
|
| 72 | BCL2, CCNA1, CCNB1, CCND1, CDKN1A, CDKN2A, MKI67, RB1
|
| Immunohistochemical expression of p53, p21/waf1, rb, p16, cyclin D1, p27, Ki67, cyclin A, cyclin B1, bcl2, bax and bak proteins and apoptotic index in normal thymus.
|
| Kanavaros P, Stefanaki K, Rontogianni D, Papalazarou D, Sgantzos M, Arvanitis D, Vamvouka C, Gorgoulis V, Siatitsas I, Agnantis NJ, Bai M.
|
| Histol Histopathol 16(4):1005-12. 2001
|
| 73 | CDKN2A, TSG9A
|
| Two regions of homozygous deletion clusters at chromosome band 9p21 in human lung cancer.
|
| Hamada K, Kohno T, Takahashi M, Yamazaki M, Tashiro H, Sugawara C, Ohwada S, Sekido Y, Minna JD, Yokota J.
|
| Genes Chromosomes Cancer 27(3):308-318 2000
|
| 74 | CDKN2A
|
| p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung.
|
| Huang CI, Taki T, Higashiyama M, Kohno N, Miyake M.
|
| Br J Cancer 82(2):374-80. 2000
|
| 75 | CDKN2A
|
| Germline CDKN2A mutation implicated in predisposition to multiple myeloma.
|
| Dilworth D, Liu L, Stewart AK, Berenson JR, Lassam N, Hogg D.
|
| Blood 95(5):1869-71. 2000
|
| 76 | CDKN2A
|
| Frequent loss of 9p21 (p16(INK4A)) and other genomic imbalances in human malignant fibrous histiocytoma.
|
| Simons A, Schepens M, Jeuken J, Sprenger S, van de Zande G, Bjerkehagen B, Forus A, Weibolt V, Molenaar I, van den Berg E, Myklebost O, Bridge J, van Kessel AG, Suijkerbuijk R.
|
| Cancer Genet Cytogenet 118(2):89-98. 2000
|
| 77 | CDKN2A
|
| A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families.
|
| Ciotti P, Struewing JP, Mantelli M, Chompret A, Avril MF, Santi PL, Tucker MA, Bianchi-Scarra G, Bressac-de Paillerets B, Goldstein AM.
|
| Am J Hum Genet 67(2):311-9. 2000
|
| 78 | CDKN2A
|
| Alterations of the INK4a/ARF locus in human intracranial germ cell tumors.
|
| Iwato M, Tachibana O, Tohma Y, Arakawa Y, Nitta H, Hasegawa M, Yamashita J, Hayashi Y.
|
| Cancer Res 60(8):2113-5. 2000
|
| 79 | CDKN2A, CDKN2B
|
| Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
|
| Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y.
|
| Cancer Genet Cytogenet 120(2):91-8. 2000
|
| 80 | CDKN2A
|
| Allelic deletion at 9p21-22 in primary cutaneous CD30(+) large cell lymphoma.
|
| Boni R, Xin H, Kamarashev J, Utzinger E, Dummer R, Kempf W, Kutzner H, Burg G.
|
| J Invest Dermatol 115(6):1104-7. 2000
|
| 81 | CDKN2A, RB1
|
| Frequent alterations in the expression of tumor suppressor genes p16INK4A and pRb in esophageal squamous cell carcinoma in the Indian population.
|
| Ralhan R, Mathew R, Arora S, Bahl R, Shukla NK, Mathur M.
|
| J Cancer Res Clin Oncol 126(11):655-60. 2000
|
| 82 | FAMMMPC, CDKN2A
|
| Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).
|
| Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W.
|
| Int J Cancer 87(6):809-11. 2000
|
| 83 | CDKN2A, CMM2
|
| Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma.
|
| Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N, Hogg D.
|
| Nat Genet 21 : 128-132. 1999
|
| 84 | CDK4, CDKN2A
|
| CDK4 gene amplification in osteosarcoma : reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons.
|
| Wei G, et al.
|
| Int J Cancer 80 : 199-204. 1999
|
| 85 | CDKN2A, CDKN2B
|
| Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival.
|
| Orlow I, et al.
|
| J Natl Cancer Inst 91(1):73-9. 1999
|
| 86 | CDKN2A
|
| p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma.
|
| Matsuda Y, et al.
|
| Gastroenterology 116(2):394-400. 1999
|
| 87 | CDKN2A, CDKN2B, IFN1@, TSG9A
|
| Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis.
|
| Watson JEV, et al.
|
| Genome Res 9(3):226-33. 1999
|
| 88 | CDKN2A
|
| High frequency of p16INK4A gene alterations in hepatocellular carcinoma.
|
| Liew CT, et al.
|
| Oncogene 18(3):789-95. 1999
|
| 89 | CDKN2A, CDKN2C
|
| Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6.
|
| Noh SJ, et al.
|
| Cancer Res 59(3):558-64. 1999
|
| 90 | RB1, CDKN2A
|
| Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer.
|
| Benedict WF, et al.
|
| Oncogene 18(5):1197-203. 1999
|
| 91 | B4GALT1, CDKN2A
|
| Down-regulation of beta1,4-galactosyltransferase gene expression by cell-cycle suppressor gene p16.
|
| Zhang SW, et al.
|
| Biochim Biophys Acta 1444(1):49-54. 1999
|
| 92 | CDKN2A
|
| Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma.
|
| Merbs SL, et al.
|
| Invest Ophthalmol Vis Sci 40(3):779-83. 1999
|
| 93 | CDKN2A
|
| The INK4A/ARF locus and its two gene products.
|
| Sharpless NE, et al.
|
| Curr Opin Genet Dev 9(1):22-30. Review. 1999
|
| 94 | CDKN2A, CDKN2B
|
| Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia.
|
| Maloney KW, et al.
|
| Blood 93(7):2380-5. 1999
|
| 95 | CDKN2A
|
| p16 mutation frequency and clinical correlation in head and neck cancer.
|
| Danahey DG, et al.
|
| Acta Otolaryngol (Stockh) 119(2):285-8. 1999
|
| 96 | CDK4, CDKN2A
|
| Normal repair of ultraviolet radiation-induced DNA damage in familial melanoma without CDKN2A or CDK4 gene mutation.
|
| Shannon JA, et al.
|
| Melanoma Res 9(2):133-7. 1999
|
| 97 | CDKN2A
|
| p16/MTS1/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation.
|
| Nakamura M, et al.
|
| Leukemia 13(6):884-90. 1999
|
| 98 | CDKN2A
|
| Tumor suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer.
|
| Riese U, et al.
|
| Int J Mol Med 4(1):61-5. 1999
|
| 99 | CDKN2A
|
| Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: Studies of CDKN2A and other genes of the pRB pathway.
|
| Berner JM, et al.
|
| Genes Chromosomes Cancer 26(2):151-160 1999
|
| 100 | CDKN2A
|
| A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs.
|
| Zhu G, et al.
|
| Am J Hum Genet 65(2):483-92 1999
|
| 101 | CDKN2A, CDKN2B
|
| Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas.
|
| Simon M, Koster G, Menon AG, Schramm J.
|
| Acta Neuropathol (Berl) 98(5):444-52 1999
|
| 102 | CDK4, CDKN2A, CMM3
|
| Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France.
|
| Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Benard J, Bressac-de Paillerets B.
|
| Hum Mol Genet 7(2):209-16. 1998
|
| 103 | CDKN2A, MTAP
|
| The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4a a gene in acute type adult T-cell leukemia.
|
| Hori Y, Hori H, Yamada Y, Carrera CJ, Tomonaga M, Kamihira S, Carson DA, Nobori T.
|
| Int J Cancer 75(1):51-6. 1998
|
| 104 | CDKN2A, CMM2
|
| CDKN2A mutations in multiple primary melanomas.
|
| Monzon J, et al.
|
| N Engl J Med 338 : 879-887. 1998
|
| 105 | CDKN2A
|
| p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas.
|
| Pinyol M, et al.
|
| Blood 91 : 2977-2984. 1998
|
| 106 | CDKN2A, CDKN2B
|
| Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
|
| Walker GJ, et al.
|
| Genes Chromosomes Cancer 22 : 157-163. 1998
|
| 107 | CDKN2A
|
| CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
|
| Nielsen GP, et al.
|
| Am J Pathol 153 : 159-163. 1998
|
| 108 | CDKN2A, CDKN2B, CMM2, TSG9A
|
| Mutations of p16 and p15 tumor suppressor genes and replication errors contribute independently to the pathogenesis of sporadic malignant melanoma.
|
| Matsumura Y, et al.
|
| Arch Dermatol Res 290 : 175-180. 1998
|
| 109 | CDKN2A, CDKN2B, CDKN2C, CDKN2D
|
| Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.
|
| Drexler HG.
|
| Leukemia 12 : 845-859. 1998
|
| 110 | CDKN2A
|
| The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2.
|
| Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G.
|
| EMBO J 17 : 5001-5014. 1998
|
| 111 | CDKN2A
|
| Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a.
|
| Russo AA, et al.
|
| Nature 395 : 237-243. 1998
|
| 112 | CDKN2A
|
| The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer.
|
| Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larsen CJ, Brambilla E.
|
| Cancer Res 58 : 3926-3931. 1998
|
| 113 | CDKN2A, TSG9A
|
| Alteration of the CDKN2A gene in pancreatic cancers : is it a late event in the progression of pancreatic cancer ?
|
| Sugimoto Y, et al.
|
| Int J Oncol 13 : 669-676. 1998
|
| 114 | CDKN1A, CDKN2A
|
| Mutation of p16, p21 or cyclin dependent kinase 4 is rare in acute lymphoblastic leukaemia.
|
| Qari MH, et al.
|
| Br J Haematol 103 : 467-472. 1998
|
| 115 | CDKN2A, CDKN2B, HLF, TCF3
|
| Different patterns of homozygous p16INK4A and P15INK4B deletions in childhood acute lymphoblastic leukemias containing distinct E2A translocations.
|
| Maloney KW, et al.
|
| Leukemia 12 : 1417-1421. 1998
|
| 116 | CDKN2A
|
| Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions : loss of intranuclear expression.
|
| Wilentz RE, Geradts J, Maynard R, Offerhaus GJ, Kang M, Goggins M, Yeo CJ, Kern SE, Hruban RH.
|
| Cancer Res 58 : 4740-4744. 1998
|
| 117 | CDKN2A
|
| p53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa.
|
| Gamieldien W, Victor TC, Mugwanya D, Stepien A, Gelderblom WC, Marasas WF, Geiger DH, van Helden PD.
|
| Int J Cancer 78 : 544-549. 1998
|
| 118 | CDKN2A
|
| Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thryoid carcinomas.
|
| Elisei R, et al.
|
| Cancer 83 : 2185-2193. 1998
|
| 119 | CDKN2A
|
| The p16 (CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients.
|
| Takita J, et al.
|
| Oncogene 17 : 3137-3143. 1998
|
| 120 | CDKN2A
|
| Deletion of the p16 gene and microsatellite instability in carcinoma arising in pleomorphic adenoma of the parotid gland.
|
| Suzuki H, et al.
|
| Diagn Mol Pathol 7(4):224-31. 1998
|
| 121 | CDKN2A, TUSC1
|
| Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.
|
| Gorgoulis VG, et al.
|
| Mol Med 4(12):807-22. 1998
|
| 122 | CDKN2A
|
| The INK4a/ARF tumor suppressor: one gene--two products--two pathways.
|
| Chin L, Pomerantz J, DePinho RA.
|
| Trends Biochem Sci 23(8):291-6. Review 1998
|
| 123 | CDKN2A, CDKN2B, MNST
|
| Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.
|
| Bahuau M, Vidaud D, Jenkins RB, Bieche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela JM, Harpey JP, Caille B, Vidaud M.
|
| Cancer Res 58(11):2298-303. 1998
|
| 124 | CDKN1A, CDKN2A, TSG9A
|
| Deletions and loss of expression of P16INK4a and P21Waf1 genes are associated with agressive variants of mantle cell lymphomas.
|
| Pinyol M, et al.
|
| Blood 89 : 272-280. 1997
|
| 125 | CDKN2A, TSG9A
|
| Point mutations can inactivate in vitro and in vivo activities of p16INK4a/CDKN2A in human glioma.
|
| Arap W, et al.
|
| Oncogene 14 : 603-609. 1997
|
| 126 | CDKN2A, TSG9A
|
| Mutations of the INK4a locus in squamous cell carcinomas of human skin.
|
| Kubo Y, et al.
|
| Biochem Biophys Res Commun 232 : 38-41. 1997
|
| 127 | CDKN2A, CDKN2B, CMM2
|
| Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF.
|
| Liu L, et al.
|
| Genes Chromosomes Cancer 19 : 52-54. 1997
|
| 128 | CDKN2A, TSG9A
|
| Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
|
| Jarrard DF, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, Cairns P, Sidransky D, Herman JG, Isaacs WB.
|
| Genes Chromosomes Cancer 19(2):90-6. 1997
|
| 129 | CDKN2A, TSG9A
|
| Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
|
| Balazs M, Carroll P, Kerschmann R, Sauter G, Waldman FM.
|
| Genes Chromosomes Cancer 19(2):84-9. 1997
|
| 130 | CDKN2A, CMM2, TSG9A
|
| Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage.
|
| Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T.
|
| Int J Cancer 74(3):255-9. 1997
|
| 131 | CDKN2A, CDKN2B, TSG9A
|
| Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes.
|
| Farrell WE, Simpson DJ, Bicknell JE, Talbot AJ, Bates AS, Clayton RN.
|
| Cancer Res 57(13):2703-9. 1997
|
| 132 | CDKN2A, TSG9A
|
| Mutation of CDKN2 is infrequently detected in myelodysplastic syndrome.
|
| Kaneko H, Horiike S, Nakao M, Yokota S, Sasai Y, Iwai T, Nakagawa H, Fujii H, Taniwaki M, Kashima K, Misawa S.
|
| Leukemia 11(8):1391-2. 1997
|
| 133 | CDKN2A
|
| Germline mutations of the CDKN2 gene in UK melanoma families.
|
| Harland M, Meloni R, Gruis N, Pinney E, Brookes S, Spurr NK, Frischauf AM, Bataille V, Peters G, Cuzick J, Selby P, Bishop DT, Bishop JN.
|
| Hum Mol Genet 6(12):2061-7. 1997
|
| 134 | CDKN2A
|
| Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene.
|
| Puig S, Ruiz A, Castel T, Volpini V, Malvehy J, Cardellach F, Lynch M, Mascaro JM, Estivill X.
|
| Hum Genet 101(3):359-64. 1997
|
| 135 | CDKN2A, TSG9A
|
| p16MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx.
|
| Jares P, Fernandez PL, Nadal A, Cazorla M, Hernandez L, Pinyol M, Hernandez S, Traserra J, Cardesa A, Campo E.
|
| Oncogene 15(12):1445-53. 1997
|
| 136 | CDKN2A, TSG1G, TSG6F, TSG10A, KLF6, TSG14B, LOH18CR1
|
| Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas : toward a genetic model of meningioma progression.
|
| Weber RG, Bostrom J, Wolter M, Baudis M, Collins VP, Reifenberger G, Lichter P.
|
| Proc Natl Acad Sci U S A 94(26):14719-24. 1997
|
| 137 | CDKN2A, CDKN2B, TSG9A
|
| Disruption of the multiple tumor suppressor gene MTS1/p16(INK4a)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias.
|
| Cayuela JM, Gardie B, Sigaux F.
|
| Blood 90(9):3720-6. 1997
|
| 138 | CDKN2A
|
| Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF.
|
| Quelle DE, et al.
|
| Proc Natl Acad Sci U S A 94 : 669-673. 1997
|
| 139 | CDKN2A
|
| Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.
|
| Kamijo T, et al.
|
| Cell 91 : 649-659. 1997
|
| 140 | CDKN2A
|
| Compilation of somatic mutations of the CDKN2 gene in human cancers : non-random distribution of base substitutions.
|
| Pollock PM, et al.
|
| Genes Chromosomes Cancer 15 : 77-88. 1996
|
| 141 | CDKN2A, TSG9A
|
| Deletion mapping indicates that MTS1 is the target of frequent deletions at chromosome 9p21 in paediatric acute lymphoblastic leukaemias.
|
| Guidal-Giroux C, et al.
|
| Br J Haematol 92 : 410-419. 1996
|
| 142 | CDKN2A, CDKN2B, CDKN2C, TSG9A
|
| Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, andCDKN2C) in childhood rhabdomyosarcoma.
|
| Iolascon A, et al.
|
| Genes Chromosomes Cancer 15 : 217-222. 1996
|
| 143 | CDKN2A, TSG9A
|
| Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas.
|
| Ono Y, et al.
|
| Acta Neuropathol 91 : 221-225. 1996
|
| 144 | D9S974, D9S975, D9S976, D9S977, D9S978, CDKN2A, CDKN2B, TSG9A
|
| Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma.
|
| Ohta M, et al.
|
| Int J Cancer 65 : 762-767. 1996
|
| 145 | CDKN2A, TSG9A
|
| Frequent loss of the P16INK4a gene product in human pituitary tumors.
|
| Woloschak M, et al.
|
| Cancer Res 56 : 2493-2496. 1996
|
| 146 | CDKN2A
|
| p16INK4A gene homozygous deletions in human acute leukaemias with alterations of chromosome 9.
|
| Faienza MF, et al.
|
| Br J Haematol 93 : 632-636. 1996
|
| 147 | CDKN2A
|
| CDNK2A (p16INK4A) somatic and germline mutations.
|
| Smith-Sšrensen B, et al.
|
| Hum Mutat 7 : 294-303. 1996
|
| 148 | CDKN2A, TSG9A
|
| Hypermethylation of the p16 gene in nasopharyngeal carcinoma.
|
| Lo KW, et al.
|
| Cancer Res 56 : 2721-2725. 1996
|
| 149 | CDK4, CDKN2A, CMM2, TSG9A
|
| Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma : analysis of a clinic-based population.
|
| Fitzgerald MG, et al.
|
| Proc Natl Acad Sci U S A 93 : 8541-8545. 1996
|
| 150 | CDKN2A, CDKN2B, CMM2, TSG9A
|
| Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas.
|
| Jagasia AA, et al.
|
| Cancer Lett 105 : 91-103. 1996
|
| 151 | CDKN2A, CMM2, TSG9A
|
| Infrequent mutation of p16INK4 in sporadic melanoma.
|
| Healy E, et al.
|
| J Invest Dermatol 107 : 318-321. 1996
|
| 152 | CDKN2A, TSG9A
|
| Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas.
|
| Fueyo J, et al.
|
| Oncogene 13 : 1615-1619. 1996
|
| 153 | CDKN2A
|
| Informative Mspl polymorphism adjacent to exon 3 of the p16INK4 (MTS1) gene.
|
| Chaubert P, et al.
|
| Mol Cell Probes 10 : 467-468. 1996
|
| 154 | CDKN2A
|
| MTS1 gene mutations in archival oral squamous cell carcinomas.
|
| Dawson CD, et al.
|
| J Oral Pathol Med 25 : 541-546. 1996
|
| 155 | CDKN2A, TSG9A
|
| Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.
|
| Barrett MT, et al.
|
| Oncogene 13 : 1867-1873. 1996
|
| 156 | CDKN2A, TSG9A
|
| MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines.
|
| Liu Q, et al.
|
| Oncogene 10 : 619-622. 1995
|
| 157 | CDKN2A, CDKN2B, TSG9A
|
| Deletion of CDK4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. (abstr)
|
| Koduru PRK, et al.
|
| Blood 86(8):2900-5. 1995
|
| 158 | TSG9A, CDKN2A
|
| Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies.
|
| Dreyling MH, et al.
|
| Blood 86 : 1931-1938. 1995
|
| 159 | CDKN2A
|
| Mutations of the CDKN2/p16ink4 gene in Australian melanoma kindreds.
|
| Walker GJ, Hussussian CJ, Flores JF, Glendening JM, Haluska FG, Dracopoli NC, Hayward NK, Fountain JW.
|
| Hum Mol Genet 4(10):1845-52. 1995
|
| 160 | TSG9A, CDKN2A, CDKN2B
|
| Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers.
|
| Suzuki H, Zhou X, Yin J, Lei J, Jiang HY, Suzuki Y, Chan T, Hannon GJ, Mergner WJ, Abraham JM, et al.
|
| Hum Mol Genet 4(10):1883-7. 1995
|
| 161 | TSG9A, CDKN2A, CMM2
|
| Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.
|
| Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, et al.
|
| Nat Genet 11 : 210-212. 1995
|
| 162 | CDKN2D, CDKN2A, CDKN2B
|
| Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4d an inhibitor of cyclin D-dependent kinases.
|
| Okuda T, Hirai H, Valentine VA, Shurtleff SA, Kidd VJ, Lahti JM, Sherr CJ, Downing JR.
|
| Genomics 29(3):623-30. 1995
|
| 163 | CDKN2A, TSG9B
|
| Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors.
|
| Rodabaugh KJ, et al.
|
| Oncogene 11 : 1249-1254. 1995
|
| 164 | CDKN2A, TSG9A
|
| Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas.
|
| Bartsch D, et al.
|
| Genes Chromosomes Cancer 14 : 189-195. 1995
|
| 165 | CDKN2A, CMM2, TSG9A
|
| Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations.
|
| Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr, et al.
|
| N Engl J Med 333 : 970-974. 1995
|
| 166 | CDKN2A, CMM2, TSG9A
|
| A familial syndrome of pancreatic cancer and melanoma with a mutation inthe CDKN2 tumor-suppressor gene.
|
| Whelan AJ, Bartsch D, Goodfellow PJ.
|
| N Engl J Med 333 : 975-977. 1995
|
| 167 | CDKN2A, TSG9A
|
| Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds.
|
| Holland EA, et al.
|
| Oncogene 11 : 2289-2294. 1995
|
| 168 | CDKN2A, TSG9A
|
| CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia.
|
| Schršder M, et al.
|
| Br J Haematol 91 : 865-870. 1995
|
| 169 | CDKN2A, TSG9A
|
| Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
|
| Herman JG, et al.
|
| Cancer Res 55 : 4525-4530. 1995
|
| 170 | CDKN2A, CDKN2B, TSG9A
|
| Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers.
|
| Shimizu T, et al.
|
| Int J Cancer 63 : 616-620. 1995
|
| 171 | CDKN2A, TSG9A
|
| Deletions and rearrangement of CDKN2 in lymphoid malignancy.
|
| Stranks G, et al.
|
| Blood 85 : 893-901. 1995
|
| 172 | CMM2, CDKN2A
|
| Mutations associated with familial melanoma impair p16ink4 function.
|
| Ranade K, et al.
|
| Nat Genet 10 : 114-116. 1995
|
| 173 | TSG9A, CDKN2A
|
| Homozygous deletions and loss of expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors.
|
| Lydiatt WM, et al.
|
| Genes Chromosomes Cancer 13 : 94-98. 1995
|
| 174 | CDKN2A, RB1, CCND1
|
| Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.
|
| Lukas J, et al.
|
| Nature 375 : 503-506. 1995
|
| 175 | CDKN2A, TSG9A
|
| Frequent loss of the cyclin-dependent kinase-4 inhibitor gene in human gliomas.
|
| Gomi A, et al.
|
| Jpn J Cancer Res 86 : 342-346. 1995
|
| 176 | CDKN2A, CMM2
|
| Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma.
|
| Liu L, et al.
|
| Oncogene 11 : 405-412. 1995
|
| 177 | TSG9A, CDKN2A
|
| p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.
|
| Williamson MP, et al.
|
| Hum Mol Genet 4 : 1569-1577. 1995
|
| 178 | CDKN2A, TSG9A, CMM2
|
| Chromosome 9p deletions in cutaneous malignant melanoma tumors : The minimal deleted region involves markers outside the p16 (CDKN2) gene.
|
| Puig S, et al.
|
| Am J Hum Genet 57 : 395-402. 1995
|
| 179 | TSG9A, CDKN2A, CDKN2B
|
| Codeletion of p15 and p16 in primary malignant mesothelioma.
|
| Xiao S, et al.
|
| Oncogene 11 : 511-515. 1995
|
| 180 | TSG9A, CDKN2A, S100A4
|
| Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas.
|
| Li YJ, et al.
|
| Oncogene 11 : 597-600. 1995
|
| 181 | CMM2, CDKN2A
|
| Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds.
|
| Gruis NA, et al.
|
| Nat Genet 10 : 351-353. 1995
|
| 182 | CDKN2A, TSG9A
|
| Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
|
| Brenner AJ, et al.
|
| Cancer Res 55 : 2892-2895. 1995
|
| 183 | CMM2, CDKN2A
|
| Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract.
|
| Igaki H, et al.
|
| Cancer Res 55 : 3421-3423. 1995
|
| 184 | CDKN2A
|
| A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies.
|
| Duro D, et al.
|
| Oncogene 11 : 21-29. 1995
|
| 185 | CDKN2A, TSG9A
|
| Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.
|
| Quelle DE, et al.
|
| Cell 83(6):993-1000. 1995
|
| 186 | CDKN2A
|
| Complex structure and regulation of the P16 (MTS1) locus.
|
| Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A.
|
| Cancer Res 55(14):2988-94. 1995
|
| 187 | CDKN2A
|
| A novel p16INK4A transcript.
|
| Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D.
|
| Cancer Res 55(14):2995-7.
1995
|
| 188 | CDKN2A
|
| Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.
|
| Nobori T, et al.
|
| Nature 368 : 753-756. 1994
|
| 189 | CDKN2A, TSG9A
|
| Rates of p16 (MTS1) mutations in primary tumors with 9p loss.
|
| Cairns P, et al.
|
| Science 265 : 415-416. 1994
|
| 190 | CDKN2A
|
| Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma.
|
| Mori T, et al.
|
| Cancer Res 54 : 3396-3397. 1994
|
| 191 | CDKN2A, CMM2
|
| Germline p16 mutations in familial melanoma.
|
| Hussussian CJ, et al.
|
| Nat Genet 8 : 15-21. 1994
|
| 192 | CDKN2A, TSG9A
|
| Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.
|
| Caldas C, et al.
|
| Nat Genet 8 : 27-32. 1994
|
| 193 | CDKN2A, TSG9A
|
| MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p.
|
| Ueki K, et al.
|
| Hum Mol Genet 3 : 1841-1845. 1994
|
| 194 | CDKN2A, TSG9A
|
| Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck.
|
| Zhang SY, et al.
|
| Cancer Res 54 : 5050-5053. 1994
|
| 195 | CDKN2A, TSG9A
|
| The MTS1 gene is frequently mutated in primary human esophageal tumors.
|
| Zhou X, et al.
|
| Oncogene 9 : 3737-3741. 1994
|
| 196 | CDKN2A, D9S598
|
| Dinucleotide repeat polymorphism adjacent to CDKN2.
|
| Herbst RA, et al.
|
| Hum Mol Genet 3 : 2265. 1994
|
| 197 | CDKN2A, TSG9A
|
| Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias.
|
| Ogawa S, et al.
|
| Blood 84 : 2431-2435. 1994
|
| 198 | CDKN2A, CMM2
|
| Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM).
|
| Cannon-Albright LA, et al.
|
| Cancer Res 54 : 6041-6044. 1994
|
| 199 | CDKN2A, TSG9A
|
| Somatic mutations of the MTS (Multiple Tumor Suppressor) 1/CDK4I(Cyclin-Dependent Kinase-4 Inhibitor) gene in human primary non-small cell lung carcinomas.
|
| Hayashi N, et al.
|
| Biochem Biophys Res Commun 202 : 1426-1430. 1994
|
| 200 | CDKN2A, CDKN2B
|
| Candidate tumor-suppressor genes MTS1 (p16ink4A) and MTS2 (p15ink4B) display frequent homozygous deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias.
|
| Hebert J, et al.
|
| Blood 84 : 4038-4044. 1994
|
| 201 | CDKN2A, TSG9A, CMM2
|
| P16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma.
|
| Cheng JQ, et al.
|
| Cancer Res 54 : 5547-5551. 1994
|
| 202 | CDKN2A, TSG9A, CDK4
|
| CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
|
| Schmidt EE, et al.
|
| Cancer Res 54 : 6321-6324. 1994
|
| 203 | CDKN2A, TSG9A
|
| Mutation rate of the CDKN2 gene in malignant gliomas.
|
| Giani C, et al.
|
| Cancer Res 54 : 6338-6339. 1994
|
| 204 | TSG9A, CDKN2A, CDKN2B
|
| Deletion of p16 and p15 genes in brain tumors.
|
| Jen J, et al.
|
| Cancer Res 54 : 6353-6358. 1994
|
| 205 | CDKN2A
|
| A cell cycle regulator potentially involved in genesis of many tumor types.
|
| Kamb A, et al.
|
| Science 264 : 436-440. 1994
|
| 206 | CMM2, CDKN2A
|
| Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.
|
| Kamb A, et al.
|
| Nat Genet 8 : 22-26. 1994
|
| 207 | CDKN2A
|
| A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
|
| Serrano M, et al.
|
| Nature 366 : 704-707. 1993
|